We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Longboat Delivery System Could Mean More Powerful Anti-Cancer Drugs

By Biotechdaily staff writers
Posted on 17 Jul 2007
Researchers are reporting the development of carbon nanotubes as a "longboat delivery system” that shows potential for addressing problems that have hindered development of more generally applicable platinum-based anticancer drugs. More...
These include analogues of the widely used and very potent drugs cisplatin, carboplatin, and oxaliplatin.

The study was published in the July 11, 2007, issue of the Journal of the American Chemical Society. The Massachusetts Institute of Technology's (MIT; Cambridge, MA, USA) Dr. Stephen J. Lippard, Ph.D., and Stanford University's (Stanford, CA, USA) Hongjie Dai, Ph.D., and colleagues noted that efforts to produce such molecules have been stalled because the required form of platinum loses activity in the body and becomes ineffective before reaching the tumor. Their answer to this problem was to develop a carbon nanotube delivery system, eventually for delivering platinum compounds safely through the body's biochemical pathways and into the tumor. Once inside the tumor cell, the compounds convert from an inactive form into an active anti-cancer drug.

The chemistry involves attaching platinum compounds to single wall carbon nanotubes (SWNTs), one-atom thick sheets of graphite rolled up into a cylinder with a diameter about 50,000 times smaller than the width of a human hair. The SWNTs act as efficient transporters for the platinum missile, carrying it to the tumor cell and then releasing the platinum as an active drug.

In one experiment with cultured cells, the SWNTs produced platinum levels inside the cells six to eight times higher than those for the platinum unit administered in the conventional way. The longboat SWNTs have the potential to carry other compounds to and into the cancer cell, as demonstrated by the co-delivery of platinum and a fluorescent dye to the cancer cell, which in the future will include tumor-targeting components.


Related Links:
Massachusetts Institute of Technology
Stanford University

Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Gold Member
Hybrid Pipette
SWITCH
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.